SERA
Sera Prognostics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.02
+2.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 70.0K | 81.0K | 77.0K | 306.0K | 268.0K |
| Cost of Revenue | 175.0K | 164.0K | 82.0K | 210.0K | 193.0K |
| Gross Profit | (105.0K) | (83.0K) | (5.0K) | 96.0K | 75.0K |
| Operating Expenses | |||||
| R&D Expense | 13.0M | 13.2M | 14.7M | 15.2M | 14.2M |
| SG&A Expense | 24.2M | 23.3M | 21.9M | 24.7M | 31.5M |
| General & Admin Expense | 16.7M | 16.7M | 16.1M | 16.3M | 16.8M |
| Selling & Marketing Expense | 7.5M | 6.5M | 5.8M | 8.3M | 14.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 37.2M | 36.4M | 36.6M | 39.9M | 45.7M |
| Cost and Expenses | 37.4M | 36.6M | 36.7M | 40.1M | 45.9M |
| Operating Income (EBIT) | (37.3M) | (36.5M) | (36.6M) | (39.8M) | (45.7M) |
| Non-Operating | |||||
| Interest Income | 3.1M | 4.6M | 2.7M | 1.6M | 456.0K |
| Interest Expense | 7.0K | 9.0K | 28.0K | 55.0K | 61.0K |
| Net Interest Income | 3.1M | 4.6M | 2.7M | 1.6M | 395.0K |
| Other Non-Op Income/Expense | 4.1M | 4.6M | 3.7M | 3.6M | 1.5M |
| Non-Operating Income (excl Interest) | (4.1M) | (4.6M) | (3.8M) | (3.6M) | (1.5M) |
| EBT (Pre-Tax Income) | (33.2M) | (31.9M) | (32.9M) | (36.2M) | (44.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (33.2M) | (31.9M) | (32.9M) | (36.2M) | (44.2M) |
| Earnings from Cont. Ops | (33.2M) | (31.9M) | (32.9M) | (36.2M) | (44.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (33.2M) | (31.9M) | (32.9M) | (36.2M) | (44.2M) |
| Per Share | |||||
| Basic EPS | ($0.67) | ($0.67) | ($0.99) | ($1.16) | ($1.43) |
| Diluted EPS | ($0.67) | ($0.67) | ($0.99) | ($1.16) | ($1.43) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 |
| Shares | |||||
| Basic Shares Outstanding | 50.5M | 47.7M | 33.2M | 31.2M | 30.9M |
| Diluted Shares Outstanding | 50.5M | 47.7M | 33.2M | 31.2M | 30.9M |
| Profitability Metrics | |||||
| EBITDA | (32.4M) | (31.0M) | (32.0M) | (35.3M) | (43.4M) |
| D&A | 842.0K | 940.0K | 833.0K | 900.0K | 756.0K |
| EBIT | (33.2M) | (31.9M) | (32.9M) | (36.2M) | (44.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026